Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 89

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 89
---
 advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. 

 59

As of December 31, 2024, our cash and cash equivalents were approximately $3.3 million and we had an accumulated deficit of approximately $563.1 million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: 

•the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; 

•the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; 

•the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; 

•the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; 

•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; 

•the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; 

•the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; 

•our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; 

•the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community; 

•our need to expand our research and development activities; 

•the costs of acquiring, licensing or investing in businesses, product candidates and technologies; 

•the effect of competing products and product candidates and other market developments; 

•the number and types of future products we develop and commercialize; 

•any product liability or other lawsuits related to our products; 

•the expenses needed to attract, hire and retain skilled personnel; 

•the costs associated with being a public company; 

•our need to implement